How do researchers and policy-makers decide on the value of health? Daniel Cressey looks at Britain's National Institute for Health and Clinical Excellence.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan
DARU Journal of Pharmaceutical Sciences Open Access 25 May 2013
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thompson Coon, J. et al. Bevacizumab, Sorafenib tosylate, Sunitinib and Temsirolimus for Renal Cell Carcinoma: A Systematic Review and Economic Evaluation (Peninsula Technology Assessment Group, 2008).
Escudier, B. et al. Lancet 370, 2103-2111 (2007).
National Institute for Health and Clinical Excellence Final Appraisal Determination: Sunitinib for the First-line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (NIH, 2009).
Additional information
See Editorial, see page 315 .
Related links
Rights and permissions
About this article
Cite this article
Cressey, D. Health economics: Life in the balance. Nature 461, 336–339 (2009). https://doi.org/10.1038/461336a
Published:
Issue Date:
DOI: https://doi.org/10.1038/461336a
This article is cited by
-
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan
DARU Journal of Pharmaceutical Sciences (2013)
